Literature DB >> 21190818

Inhibition of soluble epoxide hydrolase reduces food intake and increases metabolic rate in obese mice.

J M do Carmo1, A A da Silva, J Morgan, Y-X Jim Wang, S Munusamy, J E Hall.   

Abstract

BACKGROUND AND AIMS: This study evaluated the responses to soluble epoxide hydrolase (s-EH) inhibition, an essential enzyme in the metabolism of arachidonic acid, on food intake, body weight and metabolic parameters in mice fed a high fat-high fructose diet (HFD) for 10 weeks. METHODS AND
RESULTS: After 5 weeks of HFD, mice were divided into two groups: 1) s-EH inhibitor (AR9281, 200mg/kg/day by gavage twice daily), and 2) vehicle (0.3ml per gavage). Food intake, body weight, oxygen consumption (VO(2)), carbon dioxide production (VCO(2)), respiratory quotient (RQ), and motor activity were measured weekly for more 5 weeks. HFD increased body weight (37±1 vs. 26±1g), and plasma of glucose (316±8 vs. 188±27mg/dl), insulin (62.1±8.1 vs. 15.5±5.0μU/ml), and leptin levels (39.4±3.6 vs. 7.5±0.1ng/ml) while reducing VO(2), VCO(2) and motor activity. s-EH inhibition for 5 weeks decreased caloric intake by ~32% and increased VO(2) by ~17% (42.8±1.4 vs. 50.2±1.5ml/kg/min) leading to significant weight loss. Inhibition of s-EHi also caused significant reductions in plasma leptin levels and visceral fat content. Uncoupling protein 1 (UCP1) content in brown adipose tissue was also elevated by ~50% during s-EH inhibition compared to vehicle treatment.
CONCLUSION: These results suggest that s-EH inhibition with AR9281 promotes weight loss by reducing appetite and increasing metabolic rate, and that increased UCP1 content may contribute to the increase in energy expenditure.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21190818      PMCID: PMC3094595          DOI: 10.1016/j.numecd.2010.10.017

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  22 in total

Review 1.  New role for epoxyeicosatrienoic acids as anti-inflammatory mediators.

Authors:  W B Campbell
Journal:  Trends Pharmacol Sci       Date:  2000-04       Impact factor: 14.819

2.  An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Authors:  John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

Review 3.  Cardiometabolic syndrome and chronic kidney disease: what is the link?

Authors:  Panteleimon A Sarafidis; Adam Whaley-Connell; James R Sowers; George L Bakris
Journal:  J Cardiometab Syndr       Date:  2006

Review 4.  AMP-activated protein kinase in metabolic control and insulin signaling.

Authors:  Mhairi C Towler; D Grahame Hardie
Journal:  Circ Res       Date:  2007-02-16       Impact factor: 17.367

5.  Indispensable role of mitochondrial UCP1 for antiobesity effect of beta3-adrenergic stimulation.

Authors:  Ken-ichi Inokuma; Yuko Okamatsu-Ogura; Asako Omachi; Yukiko Matsushita; Kazuhiro Kimura; Hitoshi Yamashita; Masayuki Saito
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-12-20       Impact factor: 4.310

6.  Cytochrome P450 2C is an EDHF synthase in coronary arteries.

Authors:  B Fisslthaler; R Popp; L Kiss; M Potente; D R Harder; I Fleming; R Busse
Journal:  Nature       Date:  1999-09-30       Impact factor: 49.962

7.  Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats.

Authors:  Jeffrey J Olearczyk; Jeffrey E Quigley; Bradford C Mitchell; Tatsuo Yamamoto; In-Hae Kim; John W Newman; Ayala Luria; Bruce D Hammock; John D Imig
Journal:  Clin Sci (Lond)       Date:  2009-01       Impact factor: 6.124

8.  Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats.

Authors:  Hui Huang; Christophe Morisseau; JingFeng Wang; Tianxin Yang; John R Falck; Bruce D Hammock; Mong-Heng Wang
Journal:  Am J Physiol Renal Physiol       Date:  2007-04-18

Review 9.  Eicosanoids and renal damage in cardiometabolic syndrome.

Authors:  John D Imig
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-02       Impact factor: 4.481

10.  Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice.

Authors:  Xizhen Xu; Chun Xia Zhao; Luyun Wang; Ling Tu; Xiaosai Fang; Changlong Zheng; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang
Journal:  Diabetes       Date:  2010-01-12       Impact factor: 9.461

View more
  14 in total

1.  Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.

Authors:  Clothilde Roche; Marie Besnier; Roméo Cassel; Najah Harouki; David Coquerel; Dominique Guerrot; Lionel Nicol; Emmanuelle Loizon; Isabelle Remy-Jouet; Christophe Morisseau; Paul Mulder; Antoine Ouvrard-Pascaud; Anne-Marie Madec; Vincent Richard; Jeremy Bellien
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

Review 2.  The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.

Authors:  Xizhen Xu; Rui Li; Guangzhi Chen; Samantha L Hoopes; Darryl C Zeldin; Dao Wen Wang
Journal:  Adv Nutr       Date:  2016-11-15       Impact factor: 8.701

Review 3.  Eicosanoids, β-cell function, and diabetes.

Authors:  Pengcheng Luo; Mong-Heng Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-07-03       Impact factor: 3.072

Review 4.  Eicosanoids in metabolic syndrome.

Authors:  James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song
Journal:  Adv Pharmacol       Date:  2013

Review 5.  Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.

Authors:  Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2018-11-14       Impact factor: 11.685

6.  Neuronal Suppressor of Cytokine Signaling 3: Role in Modulating Chronic Metabolic and Cardiovascular Effects of Leptin.

Authors:  Jussara M do Carmo; Alexandre A da Silva; John Nathan Freeman; Zhen Wang; Sydney P Moak; Michael W Hankins; Heather A Drummond; John E Hall
Journal:  Hypertension       Date:  2018-04-23       Impact factor: 10.190

Review 7.  Soluble epoxide hydrolase as a therapeutic target for obesity-induced disorders: roles of gut barrier function involved.

Authors:  Jianan Zhang; Maolin Tu; Zhenhua Liu; Guodong Zhang
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2020-09-19       Impact factor: 4.006

8.  Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo.

Authors:  Suman Kundu; Talat Roome; Ashish Bhattacharjee; Kevin A Carnevale; Valentin P Yakubenko; Renliang Zhang; Sung Hee Hwang; Bruce D Hammock; Martha K Cathcart
Journal:  J Lipid Res       Date:  2012-11-15       Impact factor: 5.922

Review 9.  Obesity, kidney dysfunction and hypertension: mechanistic links.

Authors:  John E Hall; Jussara M do Carmo; Alexandre A da Silva; Zhen Wang; Michael E Hall
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 28.314

10.  Vitamin C activation of the biosynthesis of epoxyeicosatrienoic acids.

Authors:  Houli Jiang; Fiona E Harrison; Kavita Jain; Samantha Benjamin; James M May; Joan P Graves; Darryl C Zeldin; John R Falck; Bruce D Hammock; John C McGiff
Journal:  Adv Biosci Biotechnol       Date:  2012-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.